Tests BGB-43395 alone or with other drugs for advanced breast cancer
Tests a CDK4 inhibitor, alone or combined, in adults with hormone-positive breast cancer.
Plain-language title generated from the registry record
Registry title: BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Key facts
- Where
- Barretos, Brasília, Caxias do Sul, Florianópolis, Natal, Porto Algre, Rio de Janeiro, Salvador, and São Paulo, BrazilSee the 11 sites
- Phase
- Phase 1
Where in Brazil
- Fundacao Pio Xii Hospital de Amor de BarretosBarretos, BrazilTaking people
- Hospital Sirio Libanes BrasiliaBrasília, BrazilTaking people
- Fundacao Universidade de Caxias Do SulCaxias do Sul, BrazilTaking people
- Centro de Pesquisas Oncológicas CEPONFlorianópolis, BrazilTaking people
- Liga Norte Riograndene Contra O CancerNatal, BrazilTaking people
- Hospital Sao Lucas Da Pucrs Uniao Brasileira de Educacao E AssistenciaPorto Algre, BrazilTaking people
- Instituto Nacional de CâncerRio de Janeiro, BrazilTaking people
- Instituto Dor de Pesquisa E Ensino Hospital Sao RafaelSalvador, BrazilTaking people
- Clinica de pesquisa e centro de estudos em oncologia ginecológica e mamariaSão Paulo, BrazilTaking people
- Hospital Israelita Albert EinsteinSão Paulo, BrazilTaking people
- Icesp - Instituto Do Câncer Do Estado de São Paulo Octavio Frias de OliveiraSão Paulo, BrazilTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- BeOne Medicines
- Trial code
- NCT06120283EU 2023-506888-34-00
- Record updated
- 15 October 2026
- Original description
This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with fulvestrant, letrozole, or elacestrant in participants with hormone receptor positive (HR+) and human epidermal growth factor 2 negative (HER2-) breast cancer (BC) and other advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-43395.Read full original descriptionShow less
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Patients With Metastatic HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with fulvestrant, letrozole, or elacestrant in participants with hormone receptor positive (HR+) and human epidermal growth factor 2 negative (HER2-) breast cancer (BC) and other advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-43395.
Inclusion: Phase 1a (Dose Escalation): Participants with histologically or cytologically confirmed advanced, metastatic, or unresectable solid tumors associated with dependency on CDK4, including HR+ breast cancer, ovarian cancer, endometrial cancer, non-small cell lung cancer, and others. For combination with elacestrant, participants must have received at least 1 prior line of treatment for advanced/metastatic disease including prior endocrine therapy and CDK4/6 inhibitor in either the adjuvant or advanced/metastatic setting; Phase 1a Safety Expansion: For combination with fulvestrant in regions where approved and available, participants with HR+ breast cancer must have received at least 1 prior line of treatment including endocrine therapy and a CDK4/6 inhibitor. For combination with letrozole, participants must be CDK4/6 inhibitor treatment naïve and have not received any previous systemic treatment for advanced disease; Phase 1b: Participants with HR+/HER2- breast cancer; Phase 1b: For combination with fulvestrant, participants with HR+/HER2- breast cancer enrolled in regions where CDK4/6 inhibitors are approved and available must have received 1-2 lines of therapy for advanced/metastatic disease including endocrine therapy and a CDK4/6 inhibitor. Participants can have received up to 2 lines of prior cytotoxic chemotherapy for advanced disease. For combination cohorts with letrozole, participants must be CDK4/6 inhibitor treatment naïve and have not received any previous systemic treatment for advanced disease; Stable Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1; Female participants with metastatic HR+/HER2- breast cancer must be postmenopausal or receiving ovarian function suppression treatment; Adequate organ function without symptomatic visceral disease.
Exclusion: Any malignancy ≤ 3 years before the first dose of study treatment(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast); Infection requiring systemic antibacterial, antifungal, or antiviral therapy ≤ 28 days before the first dose of study drug(s), or symptomatic COVID-19 infection; Prior allogeneic stem cell transplantation, or organ transplantation; Note: Other protocol defined Inclusion/Exclusion criteria may apply; Known leptomeningeal disease or uncontrolled, untreated brain metastases; Uncontrolled diabetes; Participants with untreated chronic hepatitis B or chronic hepatitis B virus (HBV) carriers with HBV DNA ≥ 500 IU/mL (or ≥ 2500 copies/mL) at screening; Participants with active hepatitis C infection.